Skip to Content


Treatment for ADHD in Children and Adolescents

Cephalon, Inc. Provides Update on Regulatory Status of Sparlon

FRAZER, Pa., January 25, 2006 -- Cephalon, Inc. announced today that it does not expect final action from the FDA on its pending new drug application for Sparlon (modafinil) Tablets [C-IV] for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents until after the completion of several FDA advisory committee meetings. The first two panels, scheduled for February 9, 2006 and March 22, 2006, will consider safety and risk management issues associated with products in the class of currently approved ADHD treatments. Since Sparlon is not an approved drug, it will not be discussed at these meetings. A separate advisory panel to review Sparlon has been scheduled for March 23, 2006. On October 20, 2005, the FDA issued an approvable letter with respect to the company's NDA for Sparlon. The company now expects to launch Sparlon during the second quarter of 2006.

As a result of recent settlements of three patent infringement suits related to Provigil (modafinil) Tablets [C-IV], the closing of the Zeneus acquisition, the current timeline for commercial launch of Sparlon, and the impact of the recent rise in the company's stock price on the number of shares included in the income per share calculation, the Company has determined its previously issued 2006 sales and diluted adjusted income per share guidance is outdated. The Company will reissue 2006 guidance when it releases its fourth quarter and full year 2005 financial results on February 14, 2006.

Posted: January 2006

Related Articles

Sparlon (modafinil) FDA Approval History

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.